Evaluation and optimization of ELISA for detection of anti-Chlamydophila pneumoniae IgG and IgA in patients with coronary heart diseases.
We have evaluated and optimized a commercial enzyme-linked immunosorbent assay (ELISA; SeroCP Savyon, Israel), using the commercial microimmunofluorescence test (MIF; Labsystems; Helsinki, Finland) as reference method. This was done for the detection of anti-Chlamydophila pneumoniae IgG and IgA antibodies in patients with coronary heart disease (CHD). After optimization, a good agreement between the ELISA and MIF tests [IgG (P(0.05)=0.0008 and r=0.93) and IgA (P(0.05)=0.00072 and r=0.72)] was found. These ELISA tests proved to be a useful semiquantitative method for seroprevalence studies in CHD patients, with remarkable advantages over MIF test in terms of objective measurement, thus reproducibility, performance and interpretation.
Ciervo
Alessandra
A
Department of Infectious, Parasitic and Immune-mediated Diseases, Unit of Respiratory and Systemic Bacterial Diseases, Istituto Superiore di Sanità, Viale Regina Elena 299, Rome 00161, Italy. ciervo@iss.it
Petrucca
Andrea
A
Visca
Paolo
P
Cassone
Antonio
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000907:Antibodies, Bacterial / Q000097:blood*; D002690:Chlamydia Infections / Q000097:blood / Q000175:diagnosis / Q000382:microbiology*; D016993:Chlamydophila pneumoniae / Q000276:immunology*; D003327:Coronary Disease / Q000097:blood / Q000382:microbiology*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods* / Q000592:standards; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood*; D007074:Immunoglobulin G / Q000097:blood*; D008297:Male; D008856:Microscopy, Fluorescence; D008875:Middle Aged
D000907:Antibodies, Bacterial; D007070:Immunoglobulin A; D007074:Immunoglobulin G